English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

There have been significant advances in the therapeutic strategies based on monoclonal antibodies. These advances, including the modification of their format, their production, and their functionalization. have further improved their efficacy and, particularly in oncology, have helped to overcome several limitations. Nevertheless, the efficacy and safety profile of antibody drug conjugates is not yet optimal. This article primarily summarizes the challenges that need to be addressed during the development of various strategies for the discovery of antibody-drug conjugates in oncology. The authors further provide their expert opinion and perspectives for the future/ Addressing the challenges discussed in this perspective, such as by improving the specificity of targeting cancer cells, the selective site-specific conjugation of cytotoxic drugs to antibodies and developing different strategies to overcome the problem of drug resistance will likely generate a new class of ADCs and bring more value to the concept of ADCs, particularly in the treatment of cancer patients

What are the challenges involved in the strategies for future antibody-drug conjugate discovery and development for oncology?